Utilizing Autologous Multipotent Mesenchymal Stromal Cells and beta-Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F16%3A10323823" target="_blank" >RIV/00179906:_____/16:10323823 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/16:10323823 RIV/00216208:11150/16:10323823

Výsledek na webu

<a href="http://dx.doi.org/10.1155/2016/2076061" target="_blank" >http://dx.doi.org/10.1155/2016/2076061</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2016/2076061" target="_blank" >10.1155/2016/2076061</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Utilizing Autologous Multipotent Mesenchymal Stromal Cells and beta-Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial

Popis výsledku v původním jazyce

The purpose of this prospective controlled study was to compare healing quality following the implantation of ultraporous beta-tricalcium phosphate, containing either expanded autologous mesenchymal stromal cells (trial group, 9 patients) or beta-tricalcium phosphate alone (control group, 9 patients), into femoral defects during revision total hip arthroplasty. Both groups were assessed using the Harris Hip Score, radiography, and DEXA scanning at 6 weeks and 3, 6, and 12 months postoperatively. A significant difference in the bone defect healing was observed between both groups of patients (P < 0.05). In the trial group, trabecular remodeling was found in all nine patients and in the control group, in 1 patient only. Whereas, over the 12-month follow-up period, no significant difference was observed between both groups of patients in terms of the resorption of beta-tricalcium phosphate, the significant differences were documented in the presence of radiolucency and bone trabeculation through the defect (P < 0.05). Using autologous mesenchymal stromal cells combined with a beta-tricalcium phosphate scaffold is a feasible, safe, and effective approach for management of bone defects with compromised microenvironment. The clinical trial was registered at the EU Clinical Trials Register before patient recruitment has begun (EudraCT number 2012-005599-33).

Název v anglickém jazyce

Utilizing Autologous Multipotent Mesenchymal Stromal Cells and beta-Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial

Popis výsledku anglicky

The purpose of this prospective controlled study was to compare healing quality following the implantation of ultraporous beta-tricalcium phosphate, containing either expanded autologous mesenchymal stromal cells (trial group, 9 patients) or beta-tricalcium phosphate alone (control group, 9 patients), into femoral defects during revision total hip arthroplasty. Both groups were assessed using the Harris Hip Score, radiography, and DEXA scanning at 6 weeks and 3, 6, and 12 months postoperatively. A significant difference in the bone defect healing was observed between both groups of patients (P < 0.05). In the trial group, trabecular remodeling was found in all nine patients and in the control group, in 1 patient only. Whereas, over the 12-month follow-up period, no significant difference was observed between both groups of patients in terms of the resorption of beta-tricalcium phosphate, the significant differences were documented in the presence of radiolucency and bone trabeculation through the defect (P < 0.05). Using autologous mesenchymal stromal cells combined with a beta-tricalcium phosphate scaffold is a feasible, safe, and effective approach for management of bone defects with compromised microenvironment. The clinical trial was registered at the EU Clinical Trials Register before patient recruitment has begun (EudraCT number 2012-005599-33).

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FI - Traumatologie a ortopedie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13477" target="_blank" >NT13477: Užití syntetických biomateriálů k léčení rozsáhlých defektů skeletu při reimplantaci totální endoprotézy kyčelního kloubu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BioMed Research International

ISSN

2314-6133

e-ISSN

—

Svazek periodika

Neuveden

Číslo periodika v rámci svazku

9 March

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

—

Kód UT WoS článku

000374390000001

EID výsledku v databázi Scopus

2-s2.0-84965149669